What is Johnson & Johnson's opsumit/opsynvi — sales to customers (note 9)?

Johnson & Johnson (JNJ) reported opsumit/opsynvi — sales to customers (note 9) of $606.00M in Q1 2026.

How has Johnson & Johnson's opsumit/opsynvi — sales to customers (note 9) changed year-over-year?

Johnson & Johnson's opsumit/opsynvi — sales to customers (note 9) increased by 16.1% year-over-year, from $522.00M to $606.00M.

What does opsumit/opsynvi — sales to customers (note 9) mean?

The total revenue generated from the sales of specific pulmonary arterial hypertension medications.

Products & Services · Sales to customers (Note 9)

OPSUMIT/OPSYNVI — Sales to customers (Note 9)

Johnson & Johnson OPSUMIT/OPSYNVI — Sales to customers (Note 9) increased by 4.8% to $606.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.1%, from $522.00M to $606.00M. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment

CategoryGrowth

SignalHigher is better

VolatilityModerate

First reportedQ1 2024

Last reportedQ1 2026Apr 22, 2026

Rolls up toTotal Revenue

How to read this metric

An increase indicates strong market adoption and effective commercial execution for these specific therapies, while a decrease may signal increased competition or patent-related headwinds.

Detailed definition

This metric represents the total net revenue generated from the sale of specific pharmaceutical products within the pulm...

Peer comparison

Comparable to specialized therapeutic product revenue lines reported by other large-cap pharmaceutical companies in their segment disclosures.

Metric ID: jnj_segment_opsumit_opsynvi_sales_to_customers_note_9

Historical Data

7 periods

	Q1 '24	Q2 '24	Q3 '24	Q1 '25	Q2 '25	Q3 '25	Q1 '26
Value	$524.00M	$548.00M	$583.00M	$522.00M	$582.00M	$578.00M	$606.00M
QoQ Change	—	+4.6%	+6.4%	-10.5%	+11.5%	-0.7%	+4.8%
YoY Change	—	—	—	-0.4%	+6.2%	-0.9%	+16.1%

Range$522.00M – $606.00M

CAGR+10.2%

Avg YoY Growth+5.3%

Median YoY Growth+2.9%

Similar Metrics at Other Companies

United TherapeuticsUTHR View metric

InsmedINSM View metric

BiogenBIIB View metric

Frequently Asked Questions

What is Johnson & Johnson's opsumit/opsynvi — sales to customers (note 9)?: Johnson & Johnson (JNJ) reported opsumit/opsynvi — sales to customers (note 9) of $606.00M in Q1 2026.
How has Johnson & Johnson's opsumit/opsynvi — sales to customers (note 9) changed year-over-year?: Johnson & Johnson's opsumit/opsynvi — sales to customers (note 9) increased by 16.1% year-over-year, from $522.00M to $606.00M.
What does opsumit/opsynvi — sales to customers (note 9) mean?: The total revenue generated from the sales of specific pulmonary arterial hypertension medications.